A Phase 2 interventional study of Placebo and Leronlimab (700mg) in Coronavirus Disease 2019, sponsored by CytoDyn, Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-15.
Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 311th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 141st registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 484 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
CytoDyn, Inc. has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
This was a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
A single arm, non-randomized, open-label phase was added to the protocol after completion of enrollment in the randomized phase of the study.
The study had three phases: Screening Period, Treatment Period, and Follow-Up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects hospitalized with severe or critical illness caused by coronavirus 2019 infection as defined below:
A. Severe Illness:
- Diagnosed with COVID-19 by standard reverse transcriptase polymerase chain reaction (RT-PCR) assay or equivalent testing within 5 days of screening
AND
Symptoms of severe systemic illness/infection with COVID-19:
- At least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe lower respiratory symptoms including dyspnea at rest or respiratory distress
AND
Clinical signs indicative of severe systemic illness/infection with COVID-19, with at least 1 of the following:
- respiration rate (RR) ≥ 30, heart rate (HR) ≥ 125, saturated oxygen (SaO2) \<93% on room air or requires > 2L oxygen by nasal canula (NC) in order maintain SaO2 ≥93%, PaO2/FiO2 \<300 (ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen)
AND
- None of the following: Respiratory failure (defined by endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations), Septic shock (defined by systolic blood pressure (SBP) \< 90 mm Hg, or Diastolic BP \< 60 mm Hg), Multiple organ dysfunction/failure
B. Critical Illness:
- Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days of screening
AND
Evidence of critical illness, defined by at least 1 of the following:
- Respiratory failure defined based on resource utilization requiring at least 1 of the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, extracorporeal membrane oxygenation (ECMO), or clinical diagnosis of respiratory failure (in setting of resource limitation)
OR
- Shock (defined by SBP \< 90 mm Hg, or Diastolic BP \< 60 mm Hg or requiring vasopressors)
OR
-Multiple organ dysfunction/failure
Exclusion Criteria:
Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Syringes containing normal saline for injection were prepared by an unblinded pharmacist at the clinical sites for use as the placebo.
Drug: Placebo
Each vial of active contains 350mg of leronlimab at a concentration of 175mg/ml (nominal 2mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.
Drug: Leronlimab (700mg)
Each vial of active contains 350mg of leronlimab at a concentration of 175mg/ml (nominal 2mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.
Drug: Leronlimab (700mg)
Placebo
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Also known as: PRO 140
All-cause Mortality at Day 28
Incidence of mortality at day 28
Time frame: Mortality at day 28 (Visit 2, start of treatment = day 0)
All-cause Mortality at Day 14
Day 0 refers to the data of randomization/first treatment.
Time frame: Mortality at day 14 (initiation of treatment = day 0)
Proportion of Patients Achieving a Category of 6 or Higher on the Ordinal Scale at Days 14 and 28 (on a 7 Point Ordinal Scale).
Evaluation of the clinical status of participants at Day 28 was assessed with a 7-level ordinal scale (OS) (with higher score indicating better outcome). The OS of patient health status ranged from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. The study enrolled hospitalized patients with an OS Score of 2, 3, or 4 at baseline. The OS score of 6 refers to a participant who is not hospitalized with limitation on activities and 7 refers to not hospitalized with no limitations on activities.
Time frame: Change from baseline to days 14 and 28
Change in Clinical Status of Subjects at Day 28 (on a 7 Point Ordinal Scale)
Evaluation of the clinical status of participants at Day 28 was assessed with a 7-level ordinal scale (OS) (with higher score indicating better outcome). The OS of patient health status ranged from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. The study enrolled hospitalized patients with an OS Score of 2, 3, or 4 at baseline. Baseline is last available value before treatment. Change from baseline is based on patients with paired values. The p value is from rank ANCOVA model adjusted for stratification factor and age using imputed data. All results and change from baseline are based on the result of multiple imputation.
Time frame: Change from start of treatment (baseline) to day 28
Length of Hospital Stay
Length of Hospital Stay measured in days
Time frame: Timeframe is from screening visit to end of treatment (visit 5)
All-Cause Mortality at Day 14 in the Critically Ill Population
All-cause mortality at day 14 in the critically ill population. Day 0 refers to the date of randomization/first treatment.
Time frame: Mortality at day 14 (initiation of treatment = day 0)
Participants were enrolled at study sites in the United States. First patient was enrolled into Part 1 of the study (blinded portion) on 16-April-2020. Data submitted represent analysis performed on data collected after all patients completed the Follow Up period.
| Milestone | Placebo | 700mg Leronlimab | 700mg Open Label |
|---|---|---|---|
| Started | 129 | 265 | 0 |
| Completed | 125 | 259 | 0 |
| Not completed | 4 | 6 | 0 |
| Withdrew: Pt randomized to study but withdrew consent before treatment with investigational product | 6 | 0 | 4 |
| Milestone | Placebo | 700mg Leronlimab | 700mg Open Label |
|---|---|---|---|
| Started | 0 | 0 | 90 |
| Completed | 0 | 0 | 89 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Pt enrolled but withdrew consent prior to dosing | 1 | 0 | 0 |
Incidence of mortality at day 28
| Participants | 700mg Leronlimab | Placebo | 700mg Open Label |
|---|---|---|---|
| Mortality | 52 | 27 | 23 |
| Survival | 207 | 98 | 66 |
Day 0 refers to the data of randomization/first treatment.
| Participants | 700mg Leronlimab | Placebo | 700mg open label |
|---|---|---|---|
| All-cause Mortality at Day 14 | 25 | 13 | 17 |
Evaluation of the clinical status of participants at Day 28 was assessed with a 7-level ordinal scale (OS) (with higher score indicating better outcome). The OS of patient health status ranged from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. The study enrolled hospitalized patients with an OS Score of 2, 3, or 4 at baseline. The OS score of 6 refers to a participant who is not hospitalized with limitation on activities and 7 refers to not hospitalized with no limitations on activities.
| Proportion of patients | 700mg Leronlimab | Placebo | 700mg Open Label |
|---|---|---|---|
| Responders at d28 | 0.58 | 0.55 | 0.46 |
| Non-responders at d28 | 0.41 | 0.45 | 0.47 |
| Missing at d28 | 0 | 0 | 0.07 |
| Responders at d14 | 0.38 | 0.42 | 0.39 |
| Non-responders at d14 | 0.62 | 0.58 | 0.47 |
| Missing at D14 | 0 | 0 | 0.13 |
Evaluation of the clinical status of participants at Day 28 was assessed with a 7-level ordinal scale (OS) (with higher score indicating better outcome). The OS of patient health status ranged from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. The study enrolled hospitalized patients with an OS Score of 2, 3, or 4 at baseline. Baseline is last available value before treatment. Change from baseline is based on patients with paired values. The p value is from rank ANCOVA model adjusted for stratification factor and age using imputed data. All results and change from baseline are based on the result of multiple imputation.
| score on a scale | 700mg Leronlimab | Placebo | 700mg Open Label |
|---|---|---|---|
| Change in Clinical Status of Subjects at Day 28 (on a 7 Point Ordinal Scale) | 1.5 ± 2.25 | 1.4 ± 2.18 | 1.0 ± 2.1 |
Length of Hospital Stay measured in days
| Days | 700mg Leronlimab | Placebo | 700mg Open Label |
|---|---|---|---|
| Length of Hospital Stay | 15 (1 to 45) | 14 (1 to 46) | 14 (1 to 45) |
All-cause mortality at day 14 in the critically ill population. Day 0 refers to the date of randomization/first treatment.
| Participants | 700mg Leronlimab | Placebo |
|---|---|---|
| All-Cause Mortality at Day 14 in the Critically Ill Population | 2 | 5 |
Collected over Study drug was administered at Visit 2 (day 0) and visit 4 (day 7). Adverse events and medications were monitored throughout the study from Visit 2 (day 0, first treatment) through completion of follow up which is Visit 7, (4 weeks after the End of Treatment visit) for a total of 42 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 31/125 (24.8%) | 47/125 (37.6%) | 77/125 (61.6%) |
| 700mg Leronlimab | 60/259 (23.2%) | 99/259 (38.2%) | 142/259 (54.8%) |
| 700mg Open Label | 23/89 (25.8%) | 35/89 (39.3%) | 29/89 (32.6%) |
| Event | Placebo | 700mg Leronlimab | 700mg Open Label |
|---|---|---|---|
| Respiratory, Thoracic and Mediastinal DisordersRespiratory, thoracic and mediastinal disorders | 23/125 | 61/259 | 30/89 |
| Infections and InfestationsInfections and infestations | 25/125 | 38/259 | 10/89 |
| Cardiac DisordersCardiac disorders | 12/125 | 22/259 | 7/89 |
| Renal and Urinary DisordersRenal and urinary disorders | 12/125 | 16/259 | 4/89 |
| Vascular DisordersVascular disorders | 0/125 | 4/259 | 3/89 |
| Nervous System DisordersNervous system disorders | 4/125 | 6/259 | 1/89 |
| InvestigationsInvestigations | 3/125 | 7/259 | 0/89 |
| Metabolism and NutritionMetabolism and nutrition disorders | 3/125 | 6/259 | 2/89 |
| Gen Disorders and Admin Site ConditionsGeneral disorders | 3/125 | 5/259 | 0/89 |
| Gastrointestinal DisordersGastrointestinal disorders | 3/125 | 4/259 | 0/89 |
| Event | Placebo | 700mg Leronlimab | 700mg Open Label |
|---|---|---|---|
| Respiratory, Thoracic And Mediastinal DisordersRespiratory, thoracic and mediastinal disorders | 33/125 | 76/259 | 13/89 |
| Infections And InfestationsInfections and infestations | 34/125 | 60/259 | 12/89 |
| InvestigationsInvestigations | 23/125 | 26/259 | 1/89 |
| Metabolism And Nutrition DisordersMetabolism and nutrition disorders | 21/125 | 46/259 | 12/89 |
| Cardiac DisordersCardiac disorders | 21/125 | 36/259 | 10/89 |
| Gastrointestinal DisordersGastrointestinal disorders | 18/125 | 17/259 | 4/89 |
| Vascular DisordersVascular disorders | 17/125 | 21/259 | 5/89 |
| Blood And Lymphatic System DisordersBlood and lymphatic system disorders | 15/125 | 27/259 | 5/89 |
| Renal And Urinary DisordersRenal and urinary disorders | 15/125 | 30/259 | 5/89 |
| Nervous System DisordersNervous system disorders | 14/125 | 15/259 | 2/89 |
Baseline population is modified intent to treat population
| Age, Categorical(Participants) | 700mg Leronlimab | Placebo | 700mg Leronlimab - open label | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 171 | 96 | 57 | 324 |
| >=65 years | 88 | 29 | 32 | 149 |
| Age, Continuous(years) | 700mg Leronlimab | Placebo | 700mg Leronlimab - open label | Total |
|---|---|---|---|---|
| Mean | 58.82 (20 to 88) | 58.51 (28 to 86) | 59.18 (23 to 85) | 58.72 (20 to 88) |
| Sex: Female, Male(Participants) | 700mg Leronlimab | Placebo | 700mg Leronlimab - open label | Total |
|---|---|---|---|---|
| Female | 90 | 42 | 25 | 157 |
| Male | 169 | 83 | 64 | 316 |
| Race (NIH/OMB)(Participants) | 700mg Leronlimab | Placebo | 700mg Leronlimab - open label | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 11 | 7 | 1 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 29 | 23 | 17 | 69 |
| White | 133 | 70 | 54 | 257 |
| More than one race | 85 | 25 | 0 | 110 |
| Unknown or Not Reported | 0 | 0 | 17 | 17 |
| Region of Enrollment(participants) | 700mg Leronlimab | Placebo | 700mg Leronlimab - open label | Total |
|---|---|---|---|---|
| United States | 259 | 125 | 89 | 473 |
| COVID SYMPTOM SCORE(units on a scale) | 700mg Leronlimab | Placebo | 700mg Leronlimab - open label | Total |
|---|---|---|---|---|
| Mean | 3.2 (2.0 to 4.0) | 3.2 (2.0 to 4.0) | 3.3 (2.0 to 4.0) | 3.2 (2.0 to 4.0) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2020 to primary completion in Oct 2021, 18 months.
Results were first posted in Aug 2025, 3 years 10 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 18 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab